文献速递肿瘤 PET/CT

使用新型配体[68Ga]Ga-OncoFAP-DOTAGA对成纤维细胞激活蛋白(FAP)的转化成像研究

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-27

本研究建立[68Ga]Ga-OncoFAP-DOTAGA的放射性标记方法,在临床前小鼠肿瘤模型中评估其亲和力、亲脂性、稳定性及PET成像特性,并在12例患者中分析生物分布和多种肿瘤类型的摄取。结果显示该示踪剂放射性化学性质良好、快速清除、肿瘤摄取高,原发性癌症SUVmax 12.3 ± 2.3,淋巴结SUVmax 9.7 ± 8.3,远处转移SUVmax高达20.0,作者认为其可作为现有FAP示踪剂的有力替代。

要点

  • 68Ga-OncoFAP放射性合成产率高,亲和力、亲脂性和稳定性适合PET成像。
  • 小鼠FAP表达肿瘤模型中肿瘤/血比值1小时为8.6 ± 5.1,3小时为38.1 ± 33.1。
  • 12例患者临床PET/CT和PET/MRI显示原发癌SUVmax 12.3 ± 2.3,淋巴结SUVmax 9.7 ± 8.3,远处转移SUVmax高达20.0。

核心结论

  • 良好的放射性化学性质、从器官和软组织快速清除以及强烈的肿瘤摄取,证明68Ga-OncoFAP可作为现有FAP示踪剂的有力替代。

研究设计与样本

  • 转化研究,包括68Ga-OncoFAP的放射性标记、临床前动态PET/MRI小鼠皮下肿瘤模型评估,以及12例根据个体临床指征接受163 ± 50 MBq 68Ga-OncoFAP联合PET/CT和PET/MRI的患者分析。

主要发现

  • 68Ga-OncoFAP放射性合成产率高,测定的FAP亲和力、亲脂性和稳定性非常适合PET成像。
  • 临床前动态PET/MRI和伽马计数生物分布显示有益的示踪剂动力学,小鼠FAP表达肿瘤模型摄取高,肿瘤/血比值1小时为8.6 ± 5.1,3小时为38.1 ± 33.1。
  • 临床68Ga-OncoFAP-PET/CT和PET/MRI显示良好的生物分布和动力学,原发癌摄取高且可靠(SUVmax 12.3 ± 2.3),淋巴结(SUVmax 9.7 ± 8.3),远处转移(SUVmax高达20.0)。

关键数值与推荐

  • 患者接受68Ga-OncoFAP活度为163 ± 50 MBq。
  • 原发癌SUVmax 12.3 ± 2.3,淋巴结SUVmax 9.7 ± 8.3,远处转移SUVmax高达20.0。
  • 小鼠肿瘤/血比值1小时为8.6 ± 5.1,3小时为38.1 ± 33.1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The fibroblast activation protein (FAP) is an emerging target for molecular imaging and therapy in cancer. OncoFAP is a novel small organic ligand for FAP with very high affinity. In this translational study, we establish [68Ga]Ga-OncoFAP-DOTAGA (68Ga-OncoFAP) radiolabeling, benchmark its properties in preclinical imaging, and evaluate its application in clinical PET scanning. METHODS: 68Ga-OncoFAP was synthesized in a cassette-based fully automated labeling module. Lipophilicity, affinity, and serum stability of 68Ga-OncoFAP were assessed by determining logD7.4, IC50 values, and radiochemical purity. 68Ga-OncoFAP tumor uptake and imaging properties were assessed in preclinical dynamic PET/MRI in murine subcutaneous tumor models. Finally, biodistribution and uptake in a variety of tumor types were analyzed in 12 patients based on individual clinical indications that received 163 ± 50 MBq 68Ga-OncoFAP combined with PET/CT and PET/MRI. RESULTS: 68Ga-OncoFAP radiosynthesis was accomplished with high radiochemical yields. Affinity for FAP, lipophilicity, and stability of 68Ga-OncoFAP measured are ideally suited for PET imaging. PET and gamma counting-based biodistribution demonstrated beneficial tracer kinetics and high uptake in murine FAP-expressing tumor models with high tumor-to-blood ratios of 8.6 ± 5.1 at 1 h and 38.1 ± 33.1 at 3 h p.i. Clinical 68Ga-OncoFAP-PET/CT and PET/MRI demonstrated favorable biodistribution and kinetics with high and reliable uptake in primary cancers (SUVmax 12.3 ± 2.3), lymph nodes (SUVmax 9.7 ± 8.3), and distant metastases (SUVmax up to 20.0). CONCLUSION: Favorable radiochemical properties, rapid clearance from organs and soft tissues, and intense tumor uptake validate 68Ga-OncoFAP as a powerful alternative to currently available FAP tracers.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Backhaus P, Gierse F, Burg MC, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging. 2021. PMID: 34957527. doi:10.1007/s00259-021-05653-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。